Table 3 Baseline characteristics of patients with chemotherapy and no-chemotherapy in PSM group
Characteristics | No- Chemotherapy (n = 1330) | Chemotherapy (n = 1330) | Total (n = 2660) | Pc | ||||
|---|---|---|---|---|---|---|---|---|
No | % | No | % | No | % | |||
Median follow-up (months) (IQR) | 25(9–49) | 26(11–48) | 26(10–48.75) | |||||
Age (years) | 70–79 | 1046 | 78.6 | 1055 | 79.3 | 2101 | 79.0 | 0.703 |
80 + | 284 | 21.4 | 275 | 20.7 | 559 | 21.0 | ||
Race | White | 982 | 73.8 | 982 | 73.8 | 1964 | 73.8 | 1.000 |
Black | 248 | 18.7 | 248 | 18.7 | 496 | 18.7 | ||
Othera | 100 | 7.5 | 100 | 7.5 | 200 | 7.5 | ||
Marital status | Married | 608 | 45.7 | 632 | 47.5 | 1240 | 46.6 | 0.371 |
Not marriedb | 722 | 54.3 | 698 | 52.5 | 1420 | 53.4 | ||
Grade | I and II | 259 | 19.5 | 287 | 21.6 | 546 | 20.5 | 0.195 |
III | 1071 | 80.5 | 1043 | 78.4 | 2114 | 79.5 | ||
AJCC stage | I | 647 | 48.6 | 665 | 50.0 | 1312 | 49.3 | 0.645 |
II | 494 | 37.1 | 491 | 36.9 | 985 | 37.0 | ||
III | 189 | 7.1 | 174 | 13.1 | 363 | 13.6 | ||
Tumor status | T1 | 727 | 54.7 | 723 | 54.4 | 1450 | 54.5 | 0.258 |
T2 | 453 | 34.1 | 436 | 32.8 | 889 | 33.4 | ||
T3 | 83 | 6.2 | 80 | 6.0 | 163 | 6.1 | ||
T4 | 67 | 5.0 | 91 | 6.8 | 158 | 5.9 | ||
Nodal status | N0 | 990 | 74.4 | 1030 | 77.4 | 2020 | 75.9 | 0.146 |
N1 | 218 | 16.4 | 197 | 14.8 | 415 | 15.6 | ||
N2 | 67 | 5.0 | 66 | 4.9 | 133 | 5.0 | ||
N3 | 55 | 4.1 | 37 | 2.9 | 92 | 3.5 | ||
Surgery approach | No surgery | 70 | 5.3 | 67 | 5.0 | 137 | 5.2 | 0.861 |
Mastectomy and BCS | 1260 | 94.7 | 1263 | 95.0 | 2523 | 94.8 | ||
Radiation | Yes | 610 | 45.9 | 638 | 48.0 | 1248 | 46.9 | 0.294 |
No | 720 | 54.1 | 692 | 52.0 | 1412 | 53.1 | ||